Introduction
Chimeric antigen receptor (CAR) T-cell therapy is a targeted immunotherapy, demonstrating remarkable antitumor efficacy, particularly in the treatment of hematologic cancers (1, 2) . CAR T-cell therapy is a specific type of immunotherapy where T-cells are genetically modified to recognize a tumor antigen thereby specifically redirecting T cell cytolytic activity. Inspired by the success of CAR T-cell therapy in liquid tumors, there has been a great interest in expanding the use of CAR T-cells for the treatment of solid tumors, such as glioblastoma (GBM), a highly aggressive form of primary brain cancer. Several clinical trials using CAR T-cells to treat GBM have been initiated all over the world (3) (4) (5) (6) .
At this early stage of clinical development, CAR T-cells offer much promise in solid tumors. However, the diversity of current clinical trials employing varying types of CARs for different solid tumors, target patient populations, and preconditioning regimes, presents a significant challenge in identifying which aspects of a given CAR T-cell treatment protocol are most critical for its effectiveness. An additional critical challenge for CAR T-cell therapy is the potential for transient-progression, where the cancer appears to progress before eventually responding to the treatment (7, 8) .
In order to address these challenges in CAR T-cell therapy for solid tumors, we endeavored to study the kinetics of CAR T-cell killing with an in vitro system and a mathematical model. Mathematical models are useful to describe, quantify, and predict multifaceted behavior of complex systems, such as interactions between cells. A mathematical model is a formalized method to hypothesize systems dynamics, and yield solutions that represent the system's behavior under certain initial conditions. Mathematical models can be versatile and tested with clinical data which may be obtained in vivo from non-invasive imaging (9) (10) (11) . When additional information about the system becomes available, the model can be refined and adjusted accordingly. Many mathematical models have been developed to understand tumor progression to guide refinement of cancer therapy regimens (12) (13) (14) . As CAR T-cell therapy is a newly advanced treatment modality, relatively few studies have utilized computational modelling to understand and improve this cell-based therapy. Recently computational models have been developed to investigate cytokine release syndrome for toxicity management (15) (16) (17) , effect of cytokine release syndrome on CAR T-cell proliferation (18) , and mechanisms of CAR T-cell activation (19, 20) . However, it remains an open challenge how to use mathematical modeling to study and ultimately predict dynamics of CAR T-cell mediated cancer cell killing with respect to CAR T-cell dose, cancer cell proliferation, target antigen expression, and how these factors contribute to the overall effectiveness of CAR T-cell therapy.
Based upon our pre-clinical and clinical experience with our well-characterized IL13Rα2targeted CAR T-cell therapy for recurrent glioblastoma (21, 22) , we have identified several factors which contribute to the effectiveness of CAR T-cells: rates of proliferation, exhaustion, persistence, and target cell killing. To study these various facets of CAR Tcell killing kinetics, we modeled the dynamics between cancer cells and CAR T-cells as a predator prey system with the CARRGO mathematical model: Chimeric Antigen
Receptor t-cell treatment Response in GliOma. We used a real-time cell analyzer experimental system to estimate parameters of the mathematical model and then apply the model to in vivo human data with the long-term aim of developing a model which could be used to predict and eventually to optimize response.
Quick guide to equations and assumptions
The CAR T-cell treatment Response to GliOma (CARRGO) mathematical model is a variation on the classic Lotka-Volterra (23, 24) predator-prey equations: 
where represents the density of cancer cells, is the density of CAR T-cells, is the net growth rate of cancer cells, is the cancer cell carrying capacity, 2 is the killing rate of the CAR T-cells, 5 is the net rate of proliferation including exhaustion or death of CAR T-cells when encountered by a cancer cell and is the natural death rate of CAR T-cells.
The parameters , , 2 , are constants and assumed to be non-negative except for 5 which can be either positive or negative. A positive value of 5 indicates an increased rate of CAR T-cell proliferation when stimulated by interaction with a cancer cell. A negative value of 5 indicates exhaustion or limited activation of CAR T-cells resulting from interaction with a cancer cell ( Table 1) . Exhaustion and hypoactivation of CAR T-cells are combined into a single value and are not modeled individually.
We chose to model the net number of cancer cells and simple interactions between cancer cells and CAR T-cells because the output data from the culture system is limited to cell number over time. We therefore are only able to infer dynamics at this scale and dimension (cells, time). Moreover, we performed a system identifiability analysis to demonstrate the parameters of model can be uniquely determined from the data in this experiment (see supplemental methods) (25) (26) (27) (28) . Future studies may examine more complex dynamics and features such as modeling individual cell antigen levels, heterogeneity, resistant and sensitive sub populations, repeated treatments, etc. with other experimental designs which directly measure these features.
Model assumptions
The CARRGO model treats cancer cell-CAR T-cell dynamics in this experimental condition as a closed predator-prey system. The model assumes 1) the populations are well mixed, 2) cancer cell growth is limited by space and nutrients (culture media) in the in vitro culture system and therefore grow logistically, 3) CAR T-cells kill cancer cells when they interact via the law of mass action, 4) the CAR T-cell killing rate does not explicitly assume a dependence on antigen density, 5) CAR T-cells may be stimulated to proliferate or to undergo loss of effector function-defined as exhaustion-upon contact with a cancer cell (29) , and 6) the CAR T-cell death rate is independent of cancer cell density.
We chose the Logistic growth model for the cancer cell population because the fixed growth rate and carrying capacity parameters were the biological quantities of interest when comparing CAR T-cell killing kinetics across cell lines. Witzel et al compared sigmoidal growth laws including Logistic, Gompertz, and Richards showed that all these models can be fit equally well to this form of experimental data (30) . Data supporting our model assumptions are given in supplemental material1 ( Fig. S1 ,S2)
Methods

Dynamical system analysis of the CARRGO model
Closed form solutions cannot be obtained for the relatively simple CARRGO model. To study the possible dynamics with the CARRGO model, we perform classical dynamical system analysis. Detailed mathematical analysis of this model can be found in several textbooks in dynamical systems (24, 31) . In the interest of informing the reader, we briefly summarize the main points here. We begin by 1) scaling (non-dimensionalizing) the variables in the system and then 2) identify stationary points and classify their stability and finally 3) interpret the stationary points and system dynamics in terms of the initial numbers of cancer cells and CAR T-cells.
First, we scale the variables in the CARRGO model to obtain a model without physical units in order to study the intrinsic dynamics of the system. We scale time, the cancer cell and CAR T-cell populations as
. These variables are substituted into the CARRGO model (Eq.1,2) to obtain the scaled dimensionless system
The steady-state solutions . This situation predicts long-term coexistence of cancer cells and CAR T-cells, denoted P3 (red circle). In this situation, cancer cells and CAR T-cell populations increase, then decrease, then increase in an oscillatory manner. The dark blue regions shows cancer cell response and the light grey regions show cancer cell progression. We note that all 3 dynamics predicted by the CARRGO model include periods of transient increase or decrease in the cancer cell population, pointing to pseudoprogression of cancer, which a critical challenge in CAR T-cell treatment. is then a stable sink ( Fig.1c ). This case results in a transient increase in cancer cells corresponding to tumor progression followed by a decrease in tumor cells corresponding to treatment response in an oscillating manner. The transient and oscillatory nature of these dynamics may be interpreted as a "pseudo"-failure and "pseudo"-response to the therapy. We note that cancer progression and treatment occur on finite and sometimes small timescales and therefore oscillatory dynamics may not be observed in vivo due to insufficient time to observe these changes.
Cell lines
Low-passage primary brain tumor (PBT) lines were derived from GBM patients undergoing tumor resections at City of Hope as previously described (32, 33) .
Fibrosarcoma line HT1080 was obtained from the American Tissue Culture Collection (ATCC) and maintained according to recommendations. PBT030 endogenously expresses high level of IL13Ra2. HT1080 and PBT138 do not express IL13Ra2 and were lentivirally engineered to express varied levels based on different promoter strengths to investigate the relationship between killing kinetics and antigen expression level: High (>70% + ) driven by the EF1a promoter, Medium (between 40% + -70% + ) driven by the PGK promoter, Low (<20% + ) driven by the attenuated PGK100 promoter (34, 35) . These cell lines are denoted with H, M, L respectively e.x. HT1080-H. These tumor cell lines were selected because they differ in aggressiveness (proliferation rates) and antigen expression levels (endogenous or engineered).
Chimeric Antigen Receptor (CAR) T-cells were derived from healthy donor enriched CD62L+CD45RO+ central memory T cell population and lentivirally transduced with second-generation IL13Rα2-targeting CARs: IL13BBζ or IL1328ζ (32, 33, 36, 37) .
Transduced product was enriched for CAR and expanded in X-Vivo media with 10% FBS until 17 days in culture and cryopreserved. Non-transduced T cells expanded under the same condition was used as mock control.
Experimental design
Real-time monitoring of cancer cell growth was performed by using xCELLigence cell analyzer system (38) . This system utilizes electrical impedance to non-invasively quantify adherent cell density with a dimensionless number referred to as cell-index (CI). The cellindex read-out from the machine is strongly positively correlated with the number of cells in the well (r 2 > 0.9) and can be used as a linear measure of cell number (30) . We therefore 
CARRGO model fitting to experimental data
The first 24 hours of the time-series describes the process of cell attachment to the bottom of the plate (Fig. 2) . The spatial process of cell adhesion and spreading in the well can be modeled as a reaction-diffusion process, described in supplement material ( Fig. S4 ).
Since we are interested in cell growth kinetics, we omitted the data from first 24 hours during the attachment process. 
Results
Model/data fitting to in vitro data
A high goodness of fit of the CARRGO model to the xCELLigence data was observed across all cell lines ( 5 = 0.93 ± 0.1, Fig. 3, Fig. S3 ). To investigate the sensitivity of our model fitting to sampling frequency, we down-sampled the data by taking time intervals of 2 hours, 5 and 10 hours. No significant variation was observed in the model parameters 2 , 5 and to the down-sampled data (repeated measure ANOVA p>0.1)( Fig. S5, S6) .
We consistently observed very small values of the CAR T-cell death rate ( < 10 4h ).
Uniqueness of the parameters was tested by choosing 100 different combinations of values of the parameters across several orders of magnitude for the model fitting the xCELLigence data are consistent with flow cytometry measurements. This trend was observed in PBT030 and PBT138 for BBζ and 28ζ CAR T-cells and for all doses (supplementary material2 Fig. S9 ).
CAR T-cell dose-dependent dynamics
We examined the effect of varying the effector to target ratio, i.e. 
Relating , with tumor growth rate and antigen expression
Tumor growth rate varies significantly (p<0.01) among different cell-lines and with antigen expression level (see supplement material2 Fig. S11a) . To investigate the relationship between tumor growth rate and CAR T-cell killing 2 and exhaustion 5 , we evaluated cell lines with antigen levels greater than 80% and treated with BBζ CAR Tcells at an effector to target ratio of 1:5. No significant correlation was found between the cancer cell proliferation rate and killing rate ( 2 ) (Fig. S11b) . However, the exhaustion rate 5 is significantly correlated with tumor growth rate (Fig. S11c) with Pearson correlation coefficient = −0.9, p<0.001. Similar results were observed for the cells treated with 28ζ IL13Ra2-CARs. Figure 5 shows the density of IL13R 2 level on cancer cell surface and its relation to CAR T-cell killing for cell line HT1080-H and PBT138-H.
We observed that 2 shows a decreasing trend from medium to high antigen level ( Fig.5c) suggesting that high levels of antigen expression may not result in faster rates of CAR Tcell killing. The rate constant 5 increases from low to medium antigen expression and plateaus with high levels (Fig.5d ). This suggests limited activation of CAR T-cell at lower antigen expression and exhaustion rate from medium to high antigen may not change significantly and may be the result of over-activation of the CAR T-cells. . CAR T-cell killing rate is observed to decrease with increasing ET ratio for all cell lines. This suggests CAR T-cells kill more cancer cells per unit time at a lower concentration as compared to higher ET ratio. In contrast, the CAR T-cell proliferation / exhaustion rate increases with ET ratio. This suggests that the CAR T-cells are stimulated to proliferate and are less exhausted with higher ET ratio as compared to lower. For reference, CAR T-cells are hypoactivated in mock ( 5 < 0). The CAR T-cell death rate, or persistence, is observed to be independent of target cell line and ET ratio. . CAR T-cell killing rate is observed to decrease with increasing ET ratio for all cell lines. This suggests CAR T-cells kill more cancer cells per unit time at a lower concentration as compared to higher ET ratio. In contrast, the CAR T-cell proliferation / exhaustion rate increases with ET ratio. This suggests that the CAR T-cells are stimulated to proliferate and are less exhausted with higher ET ratio as compared to lower. For reference, CAR Tcells are hypoactiveted in mock (κ 2 < 0). The CAR T-cell death rate, or persistence, is observed to be independent of target cell line and ET ratio.
CARRGO model applied to in vivo human data
To translate the in vitro dynamics to of the model to real patient data (22) , we fit the CARRGO model to MRI-derived tumor volume data during CAR T-cell treatment (Fig. 6 ).
The CARRGO model is able to fit the tumor growth dynamics quite accurately for lesions T6, and T7 with the same set of parameters 2 = 6 × 10 4• (day -1 cell -1 ), 5 = 0.3 × 10 42'
(day -1 cell -1 ), = 0.1 × 10 4' (day -1 ) and lesion T9 with 2 = 9 × 10 4" (day -1 cell -1 ), 5 = −2 × 10 42h (day -1 cell -1 ), = 5 × 10 4' (day -1 ). In the case of lesion T9, although the CARRGO model is consistent with the overall tumor dynamics, it does not fit the later time points following CAR T-cell treatment well. This is because lesion T9 received radiation treatment between day 200 to 300, which is not included in the CARRGO model. We note the negative correlation between the tumor growth rate ( = 0.06, 0.07 /day and = 0.2 /day for T6, T7 and T9 respectively) with the CAR T-cell exhaustion rate 5 in the patient data, which is consistent with that observed in the experimental data (Fig. S11c) . We remark that the parameters 2 and 5 are on the order of (10 42h ), which appear to be very small, however, these parameters are scaled by the caring capacity in units of cells, which is of order (10 • ). Therefore, these parameter values are comparable with the in vitro data when scaled relative to the carrying capacity (Fig. 4) 
Discussion
The We observed that the cancer cell growth showed no relation with CAR T-cell killing rate and an inverse relationship with 5 . This may explain variations in patient-specific responses even for the same CAR T-cell dose. For a fixed CAR T-dose, 5 is the principle determinant of treatment failure or success as shown in phase plane analysis (Fig.1) , which is also observed in patient data (Fig.6 ). This result, driven by the CARRGO model analysis suggests that the balance between proliferation and exhaustion of CAR T-cells may contribute more than the rate of CAR T-cell mediated cancer cell killing in determining treatment success or failure. Moreover, the CARRGO model predicts transient progression of cancer cells even in the case of successful CAR T-cell therapy.
This prediction may be consistent with the clinical phenomenon of pseudo-progression, in which the cancer is seen to progress during therapy before eventually responding (7, 8) .
Identifying characteristics of the patient and the CAR T-cells which may result in pseudoprogression could have a profound effect on interpretation of these dynamics observed in the clinic.
Interestingly, we found 2 decreases and 5 plateaued from medium antigen level to higher level of antigen expression. One of the possible explanations of this behavior could be the antigen density is more heterogeneous in the higher antigen level cell population as compared to medium and low antigen levels (Fig.5a ). A ore heterogeneity in the density of antigen expression intensity in the cancer cells within the initial population may cause clustering of CAR T-cells resulting in their exhaustion (20, 40) . Another confounding factor can be the dependence of the detected antigen signal intensity on both the number Figure 1 ) and rapid progression for HT1080-H (case 2, Figure 1 ). . CAR T-cell killing rate is observed to decrease with increasing ET ratio for all cell lines. This suggests CAR T-cells kill more cancer cells per unit time at a lower concentration as compared to higher ET ratio. In contrast, the CAR T-cell proliferation / exhaustion rate increases with ET ratio. This suggests that the CAR T-cells are stimulated to proliferate and are less exhausted with higher ET ratio as compared to lower. For reference, CAR Tcells are hypoactiveted in mock (κ 2 < 0). The CAR T-cell death rate, or persistence, is observed to be independent of target cell line and ET ratio. . κ 1 shows a decreasing trend from medium to high antigen levels (c) suggesting that high levels of antigen expression may not result in faster rates of CAR T-cell killing(d). κ 2 increases from low to medium antigen expression and plateaus with high antigen levels(d). This suggests limited activation of CAR T-cell at lower antigen expression and that exhaustion rates from medium to high antigen may not change significantly. 
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